These effects, together with the increased concentration before treatment, indicate that PON3 is not associated with the presence of sub-clinical atherosclerosis in HIV-infected patients, although lipid peroxidation and atherosclerosis are known to be strongly linked to such infection [116]. Here, PON3 is linked to infection.